Telehealth Narcolepsy Prescribing: What Psychiatric NPs Can Do in Georgia

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients via telehealth, you’re stepping into a clinical niche where expertise is desperately needed – but the regulatory landscape can feel like navigating a maze blindfolded. Between DEA waivers that keep getting extended, state-by-state prescribing restrictions that vary wildly, and medication shortages that haven’t let up since 2022, narcolepsy prescribing is far from straightforward.

Here’s the reality: Narcolepsy affects roughly 1 in 2,000 Americans – about 160,000 people living with a condition that can trigger sudden sleep attacks mid-conversation or while driving. Yet most of these patients struggle to access specialized care. Why? Because narcolepsy treatment typically requires prescribing controlled stimulants (Schedule II drugs like Adderall or methylphenidate) or other tightly regulated medications, and not every provider is willing or able to navigate the compliance requirements, especially via telehealth.

For psychiatrists, the opportunity is clear: you have full prescriptive authority and the clinical background to manage these complex cases. For PMHNPs, the picture is murkier – your ability to prescribe narcolepsy medications independently depends entirely on which state you’re licensed in. Some states grant you near-physician-level autonomy after a few years of experience. Others won’t let you write a single Schedule II prescription outside a hospital setting.

This article cuts through the confusion. We’ll cover:

• Current federal telehealth rules for controlled substances (and what happens when the DEA waiver expires)
• State-by-state prescribing authority for psychiatrists vs. PMHNPs
• The real clinical and administrative challenges of managing narcolepsy meds remotely
• Reimbursement realities and how to make narcolepsy medication management financially viable
• Practical workflows to stay compliant while delivering quality care

Whether you’re already treating narcolepsy patients or thinking about adding this specialty to your telehealth practice, here’s what you need to know.

Federal Telehealth Rules: The DEA Waiver Extension Through 2025

Let’s start with the big picture: Can you legally prescribe Schedule II stimulants for narcolepsy via telehealth without seeing the patient in person?

As of early 2026, the answer is yes – but with a major asterisk.

During the COVID-19 public health emergency, the DEA suspended the Ryan Haight Act requirement that controlled substances could only be prescribed after an in-person medical evaluation. This temporary waiver has been repeatedly extended, most recently through the end of 2025. This means psychiatrists and authorized nurse practitioners can currently prescribe medications like Adderall, Ritalin, modafinil, and even sodium oxybate for narcolepsy patients they’ve never met face-to-face, as long as the encounter meets standard telehealth requirements (video-based evaluation, proper patient identification, documentation of medical necessity, etc.).

But here’s what keeps providers up at night: What happens in 2026?

The DEA has been working on permanent telehealth prescribing rules for years. When (not if) they finalize these regulations, providers may need to either:

• See patients in person at least once before prescribing controlled substances remotely, or
• Obtain a special DEA telemedicine registration to continue pure virtual prescribing

Most providers I talk to are preparing for both scenarios. Some are building partnerships with local physicians or clinics who can handle initial in-person evaluations. Others are watching the DEA rulemaking process closely, hoping for a reasonable middle ground that doesn’t destroy the telehealth access gains of the past few years.

Practical takeaway: For now, leverage the extended waiver. Build your narcolepsy practice, document everything meticulously, and stay plugged into DEA updates. If you’re treating patients across multiple states, having a backup plan for in-person initial visits will make any transition smoother.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

How Psychiatrists Can Manage Narcolepsy via Telehealth (Full Scope, Zero Restrictions*)

If you’re a board-certified psychiatrist (MD or DO), your prescriptive authority for narcolepsy is straightforward in most scenarios: you can prescribe anything the patient needs, assuming you’re licensed in their state and following standard telehealth protocols.

What Psychiatrists Can Do:

Initial Evaluations: You can conduct comprehensive narcolepsy assessments via video, including:

• Detailed sleep history and symptom review (Epworth Sleepiness Scale, frequency of sleep attacks, presence of cataplexy)
• Reviewing sleep study results (polysomnography/MSLT) – most patients will come to you with these already completed by a sleep specialist
• Ruling out mimickers like sleep apnea, depression, or medication side effects
• Ordering additional workups if needed (labs for thyroid function, referrals for repeat sleep studies)

Medication Initiation: Once you’ve confirmed the diagnosis, you can start first-line therapies:

• Modafinil or armodafinil (Schedule IV wakefulness promoters) – usually the first choice
• Methylphenidate or amphetamine stimulants (Schedule II) – for patients who need stronger symptom control
• Sodium oxybate (Schedule III, REMS program) – for narcolepsy with cataplexy, though you’ll need to enroll in the restricted distribution program
• Newer agents like pitolisant or solriamfetol – often requiring prior authorization but valuable for patients who can’t tolerate stimulants

Ongoing Management: Monthly follow-ups (often required for Schedule II refills anyway) to monitor:

• Symptom improvement (fewer sleep attacks, better daytime function)
• Side effects (blood pressure, heart rate, weight changes, insomnia)
• Medication misuse risks (PDMP checks before every controlled substance prescription)
• Coordination with sleep specialists or primary care for comorbid conditions

The Reality Nobody Talks About: Even though psychiatrists have full authority, state telehealth laws can still create barriers. For example:

• Florida prohibits telehealth prescribing of Schedule II controlled substances unless the condition is psychiatric, the patient is in a hospital/hospice, or it’s chronic pain management. Since narcolepsy is neurological (not psychiatric), a strict reading means you’d need at least one in-person visit to prescribe Adderall via telehealth in Florida – or you’d need to rely on Schedule IV alternatives like modafinil.

• Audio-visual requirements are nearly universal. Phone-only visits won’t cut it for controlled substance prescribing in most states, even for established patients.

• PDMP checks are mandatory in almost every state before writing controlled prescriptions. Some states (like New York) require you to check the database every single time, which adds a few minutes to each visit but is non-negotiable.

Still, compared to NPs navigating patchwork scope restrictions, psychiatrists have it easy. The workflow is clinically driven rather than legally constrained.

PMHNP Prescribing Authority: It Depends Entirely on Your State

Here’s where things get complicated. If you’re a PMHNP, your ability to manage narcolepsy independently hinges on state scope-of-practice laws that vary dramatically.

Full Practice States (After Meeting Requirements):

California: Under AB 890, experienced NPs can become fully independent ‘104 NPs’ starting in 2026, after working 3+ years in a physician-supervised setting. Until then, you’ll need standardized procedures signed by a collaborating physician for Schedule II prescribing. It’s workable, but requires physician partnership.

New York: After 3,600 hours of practice (about 2 years full-time), you no longer need a collaborative agreement. An experienced NY PMHNP can prescribe narcolepsy medications – including Schedule II stimulants – completely independently. You’ll still need to check the I-STOP PDMP every time and e-prescribe all controlled substances, but there are no physician oversight requirements.

Illinois: Full Practice Authority (FPA) is available after 4,000 clinical hours plus 250 hours of pharmacology CE. Once you have FPA, you can prescribe Schedule II–V independently. Illinois does require physician consultation for ongoing Schedule II opioids and long-term benzodiazepines, but not for stimulants – meaning narcolepsy management is fair game. This makes Illinois one of the most PMHNP-friendly states for this work.

Restricted Practice States (Physician Collaboration Required):

Texas: This is the most restrictive major state for NPs. You must have a Prescriptive Authority Agreement with a supervising physician, AND Texas law prohibits NPs from prescribing Schedule II drugs for outpatients except in hospital/hospice settings. Translation: You cannot prescribe Adderall or Ritalin for a narcolepsy patient in Texas. Your supervising physician would need to write those prescriptions, or you’d manage patients exclusively with Schedule IV alternatives like modafinil.

Florida: PMHNPs require physician collaboration (psychiatric NPs were excluded from the state’s autonomous practice law). Even with a collaborating MD, Florida limits NP Schedule II prescriptions to a 7-day supply – unless you’re a certified ‘psychiatric nurse’ prescribing psychiatric medications. Since narcolepsy isn’t psychiatric, you’d technically be stuck writing weekly prescriptions for stimulants, which is administratively untenable. Most Florida NPs either have their collaborating psychiatrist handle stimulant prescriptions or focus on modafinil.

Pennsylvania: NPs need a written collaborative agreement with a physician. You can prescribe Schedule II drugs, but only up to a 30-day supply (requiring monthly physician notification). Schedule III–IV can be prescribed for 90 days. This aligns reasonably well with narcolepsy care (monthly visits are standard anyway), but you’ll need that physician partnership documented.

State-by-State Summary Table:

Bottom Line for PMHNPs: If you want to independently manage narcolepsy via telehealth, target states like New York and Illinois where experienced NPs have full authority. In states like Texas and Florida, you’ll need a physician partner willing to supervise or co-prescribe – which our platform can help facilitate, but it’s not true independence.

The Real Clinical Challenges Nobody Warns You About

Managing narcolepsy via telehealth isn’t just about knowing the laws. Here are the operational realities providers face:

1. Confirming the Diagnosis

Unlike ADHD or depression, you typically can’t diagnose narcolepsy from a clinical interview alone. The gold standard requires:

• Overnight polysomnography (to rule out sleep apnea)
• Multiple Sleep Latency Test (MSLT) showing shortened sleep onset and REM intrusions

Most narcolepsy patients arrive with these studies already completed, referred by sleep specialists who don’t manage medications long-term. But what if they don’t? In telehealth, coordinating local sleep studies adds complexity. You’ll need referral networks or protocols for patients who need diagnostic workups before you can ethically prescribe.

2. The Adderall Shortage (Still Ongoing)

Since mid-2022, intermittent amphetamine shortages have plagued narcolepsy patients. One week a pharmacy has stock, the next week it’s dry for months. Patients call panicked – they’re falling asleep at work, can’t drive safely, and you’re suddenly scrambling to:

• Find alternative pharmacies
• Switch to methylphenidate or modafinil
• Re-titrate doses and manage the transition

This isn’t a minor inconvenience. For providers, it means unplanned phone calls, emergency appointment slots, and constant workarounds. Telehealth platforms with multi-state pharmacy networks can help, but it’s still a pain point that won’t fully resolve until DEA/FDA adjust manufacturing quotas.

3. Prior Authorizations Are Brutal

Newer narcolepsy medications (pitolisant, solriamfetol) and even modafinil often require prior authorization. Insurers want:

• Sleep study documentation proving narcolepsy
• Evidence that cheaper alternatives (like generic stimulants) were tried first
• Chart notes justifying medical necessity

You’re not getting paid for the 30–60 minutes this takes. It’s just part of serving these patients. Some providers build PA fees into cash-pay models or use services that handle authorizations, but it’s a time sink either way.

4. Monitoring and Safety Protocols

Narcolepsy patients on stimulants need regular monitoring:

• Blood pressure and heart rate checks (often done at home with patient-owned devices in telehealth)
• PDMP queries before every controlled prescription (mandatory in most states)
• Documentation of symptom improvement (Epworth scores, sleep attack frequency logs)
• Screening for misuse (stimulant abuse is rare in true narcolepsy but must be monitored)

These workflows need to be systematized. Quick 15-minute med checks can balloon into 30-minute sessions if you’re not efficient.

5. Sodium Oxybate Requires Special Enrollment

If you’re treating narcolepsy with cataplexy, you may prescribe Xyrem or Xywav (sodium oxybate). These require:

• Provider enrollment in the REMS (Risk Evaluation and Mitigation Strategy) program
• Coordination with the single central pharmacy that dispenses these drugs
• Patient counseling on serious risks (respiratory depression, complex sleep behaviors)

It’s doable, but adds another layer of administrative complexity that general psychiatric prescribing doesn’t involve.

Reimbursement: Can You Actually Make Money Managing Narcolepsy Meds?

Let’s talk economics. Narcolepsy medication management typically involves:

• Initial evaluation: 30–45 minutes (code as 99204 or 99205 for new patients)
• Follow-up visits: 15–20 minutes monthly during titration, then every 3 months when stable (typically 99213 or 99214)

Insurance Reimbursement:

Most states now mandate telehealth payment parity, meaning your video visit is reimbursed at the same rate as in-person. For psychiatrists:

• A 99214 med check might net $110–$140 (varies by payer and region)
• Monthly visits for a stable narcolepsy patient = ~$1,200–$1,500/year per patient before overhead

For PMHNPs, Medicare reimburses at 85% of physician rates when billing under your own NPI. Private insurance varies – many pay NPs at parity, but historical data shows mental health providers overall get paid about 22% less than other specialists, driving many to opt out of panels.

The Cash-Pay Alternative:

Given the hassles with prior authorizations and lower mental health reimbursement, many providers offer cash-pay narcolepsy management:

• Monthly subscription models ($150–$250/month including unlimited messaging and refills)
• Per-visit fees ($125–$200 for med checks)

Narcolepsy patients are often desperate for accessible, knowledgeable providers. In shortage areas (rural regions, states like Texas with terrible access), they’ll pay out-of-pocket if it means consistent care.

ROI Compared to DIY Marketing:

Here’s the business case for platforms like Klarity versus trying to build your own narcolepsy patient panel:

DIY Marketing Reality:

• SEO takes 6–12 months of consistent investment before generating meaningful leads
• Google Ads for ‘narcolepsy treatment near me’ or similar psychiatric keywords cost $15–$40+ per click
• Realistic cost per booked patient through PPC: $200–$400+ when you factor in ad spend, click-through rates, and no-shows
• Psychology Today or Zocdoc charge monthly fees ($30–$300/month) PLUS you’re competing with hundreds of other providers on the same listings
• Total monthly marketing spend for a solo provider trying to fill a panel: $3,000–$5,000 with uncertain ROI

Platform Model (Klarity):

• Pay-per-appointment model: you pay a standard listing fee only when a pre-qualified patient books with you
• No upfront ad spend or monthly subscriptions
• Patients are already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow

Instead of gambling $4,000/month on marketing with zero guarantee of results, you pay only when you see qualified patients. That’s guaranteed ROI vs. marketing risk.

Practical Workflows for Compliant Narcolepsy Prescribing

Here’s how to structure your narcolepsy telehealth practice to stay efficient and compliant:

Initial Visit Checklist:

• [ ] Verify patient identity and location (required for licensure)
• [ ] Obtain telehealth informed consent
• [ ] Review sleep study results (request upload before visit)
• [ ] Document comprehensive sleep/medical history
• [ ] Screen for contraindications (cardiac history, substance use)
• [ ] Check state PDMP before prescribing any controlled substance
• [ ] Educate on medication expectations, side effects, and safety
• [ ] Use EPCS (Electronic Prescribing of Controlled Substances) for all prescriptions
• [ ] Schedule follow-up within 2–4 weeks for initial titration

Monthly Follow-Up Template:

• [ ] Update symptom severity (Epworth Sleepiness Scale, sleep attack frequency)
• [ ] Review medication adherence and side effects
• [ ] Check blood pressure if on stimulants (patient self-reports from home device)
• [ ] Query PDMP for any new controlled prescriptions from other providers
• [ ] Adjust dose or switch medications as needed
• [ ] Document everything as if it were an in-person visit
• [ ] E-prescribe next month’s supply (Schedule II requires new script each time – no refills)

State-Specific Compliance Additions:

• Florida: Use audio-visual platform; consider Schedule IV alternatives to avoid Schedule II telehealth restrictions
• Texas: If NP, coordinate with supervising physician for Schedule II scripts
• New York: Document I-STOP PDMP check every visit; use only approved e-prescribing platforms
• Pennsylvania: If NP, ensure collaborative agreement explicitly authorizes narcolepsy medications
• California: If NP without 104 status, verify standardized procedures cover stimulants

Red Flags Requiring MD Backup or Referral:

• Diagnostic uncertainty (patient never had sleep study, symptoms don’t fit classic narcolepsy)
• Severe cardiovascular disease (significant stimulant contraindication)
• Active substance use disorder (high misuse risk)
• Uncontrolled hypertension on stimulants (needs specialist management)
• Complex cataplexy requiring sodium oxybate initiation (if you’re not REMS-enrolled)

State Telehealth Laws: What Actually Matters for Narcolepsy Prescribing

Beyond scope-of-practice issues, state telehealth regulations add another layer:

Key State Rules:

Florida: Schedule II prescribing via telehealth is prohibited unless treating a psychiatric disorder, managing chronic pain, or patient is in hospital/hospice. Since narcolepsy is neurological, technically you need an in-person visit first – or rely on modafinil (Schedule IV, which became telemedicine-permissible under SB 312 in 2022).

Texas: Telehealth is allowed, but you must establish a valid practitioner-patient relationship (video required, not audio-only). No specific controlled substance telehealth ban beyond federal rules.

New York: Fully supports telehealth parity. Commercial insurers must cover telehealth at same rate as in-person. No additional restrictions on controlled substance prescribing via video beyond PDMP requirements.

California: Strong telehealth parity laws; no prohibition on controlled substance prescribing via telemedicine. Audio-only technically allowed for some services, but for controlled substances, audio-visual is standard practice.

Pennsylvania: Telehealth permitted with standard of care equivalent to in-person. No special controlled substance telehealth ban.

Cross-State Practice: Remember, you must be licensed in the patient’s state to prescribe. Interstate compacts don’t cover physician or NP prescribing – you need full licensure in each state where your patients reside. Platforms can help streamline multi-state licensing, but it’s still time and money to maintain.

FAQ: Narcolepsy Prescribing Questions Providers Actually Ask

Q: Can I diagnose narcolepsy via telehealth, or do patients need prior sleep studies?

A: Standard of care requires objective sleep testing (polysomnography + MSLT) to confirm narcolepsy before starting long-term controlled substances. Most telehealth providers manage patients already diagnosed by sleep specialists, or coordinate local sleep study referrals before prescribing. You can do the clinical assessment via video, but ordering the diagnostic tests typically requires local coordination.

Q: What’s the difference between managing narcolepsy vs. ADHD with stimulants?

A: Clinically, narcolepsy often requires higher stimulant doses and sometimes multiple daily doses (wake-up dose + midday dose). Patients may also need adjunct therapies like antidepressants for cataplexy or sedatives for disrupted nighttime sleep – polypharmacy is more common. Administratively, narcolepsy usually requires prior authorization proving the diagnosis with sleep studies, whereas ADHD typically doesn’t.

Q: How do I handle the Adderall shortage with my narcolepsy patients?

A: Have backup medication options ready: switch to methylphenidate, modafinil, armodafinil, or newer agents like solriamfetol. Build relationships with multiple pharmacies or use telehealth pharmacy partners who can ship nationally. Communicate proactively with patients about potential shortages and have contingency prescriptions ready.

Q: If I’m a PMHNP in a restricted state, can I manage narcolepsy at all?

A: Yes, but with limitations. In Texas, you’d need your supervising physician to prescribe Schedule II stimulants while you manage modafinil and follow-up care. In Florida, you can prescribe but only 7-day supplies of Schedule II (impractical for ongoing care). In Pennsylvania, you can prescribe up to 30-day supplies with physician oversight. Partner with a collaborating physician willing to support narcolepsy care, or focus on states where you have full authority.

Q: Do I need malpractice insurance endorsement for prescribing controlled substances via telehealth?

A: Most malpractice carriers cover telehealth prescribing as long as you follow evidence-based guidelines and document appropriately. Verify your policy covers controlled substance prescribing and multi-state practice if applicable. Following PDMP requirements, obtaining proper informed consent, and maintaining thorough records protects you legally.

Q: Can I bill the same E/M codes for narcolepsy medication management as I would for depression or anxiety?

A: Yes. Narcolepsy med checks are coded like any other medication management visit (99213, 99214, etc.). Since narcolepsy has a medical diagnosis code (ICD-10 G47.4x), some insurers may process it under medical benefits rather than behavioral health, potentially improving reimbursement or avoiding mental health carve-outs. Code according to time/complexity as you would any med check.

Q: What happens to telehealth controlled substance prescribing after the DEA waiver expires?

A: The current extension runs through end of 2025. The DEA is drafting permanent telemedicine rules which may require an initial in-person visit or special DEA telemedicine registration. Stay informed through professional organizations (APA, AANP) and be prepared to adapt – either by arranging in-person initial evaluations or obtaining whatever new registration the DEA implements.

Why Klarity Is Built for Narcolepsy Prescribers

Managing narcolepsy remotely is clinically rewarding – you’re helping patients with a debilitating condition access specialized care they often can’t find locally. But between regulatory complexity, medication shortages, and reimbursement challenges, it can feel overwhelming to build this into your practice.

That’s where a platform approach makes sense. Instead of spending months and thousands of dollars trying to attract narcolepsy patients through SEO or Google Ads (with no guarantee anyone will book), you get:

• Pre-qualified patient flow already matched to your specialty and state licensure
• Pay-per-appointment model – you only pay when a patient books, eliminating marketing risk
• Built-in telehealth infrastructure including EPCS and PDMP integrations
• Compliance support for multi-state practice and scope-of-practice variations
• Both insurance and cash-pay options so you can choose your revenue model

For PMHNPs in restricted states, we can facilitate physician collaborative agreements. For all providers, we handle the administrative heavy lifting so you can focus on what you do best – helping patients manage their symptoms and reclaim their lives.

Whether you’re a psychiatrist looking to expand into telehealth or an experienced PMHNP ready to leverage your full scope, narcolepsy care is an underserved niche where your expertise genuinely matters. The regulations are navigable, the demand is real, and the economics work – especially when you’re not gambling thousands on marketing every month.

Ready to explore treating narcolepsy patients via telehealth? Join Klarity’s provider network and start seeing qualified patients who actually need what you offer – without the marketing headaches or upfront costs.

References

1. Axios (Nov 18, 2024). ‘COVID-era telehealth prescribing extended again for Adderall, other controlled substances.’ https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

2. Texas Medical Board. ‘Who can prescribe Schedule II drugs under physician delegation?’ https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation

3. California Board of Registered Nursing. ‘AB 890 Nurse Practitioner Practice.’ https://www.rn.ca.gov/practice/ab890.shtml

4. Florida Statutes, Section 464.012 (2021). ‘Nurse Practice Act – Prescribing limitations.’ https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All

5. Rivkin Radler LLP (Apr 13, 2022). ‘New Law Allows Experienced NPs to Practice Independently in NY.’ https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority